New hope for tired prostate cancer patients: low dose naltrexone tested in clinical trial
NCT ID NCT07224009
First seen Nov 03, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests whether a small daily dose of naltrexone (3 mg) can reduce fatigue in men with prostate cancer who are receiving hormone therapy (ADT). The trial will enroll 60 participants and measure changes in tiredness, quality of life, and safety. It is a Phase 2 study, meaning it is still early but aims to see if the treatment works and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.